Journal
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume 62, Issue 4, Pages 646-654Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2009.05.030
Keywords
adalimumab; alefacept; clinical trials; efalizumab; etanercept; infliximab
Categories
Funding
- Galderma Laboratories LP
Ask authors/readers for more resources
Pyoderma gangrenosum is a rare and often painful skin disease that can be unpredictable in its response to treatment. There is currently no gold standard of treatment or published algorithm for choice of therapy. The majority of data comes from case studies that lack a standard protocol not only for treatment administration but also for the objective assessment of lesion response to a specific therapy. This review provides an update to the treatment of pyoderma gangrenosum with a particular focus on new systemic therapies. (J Am Acad Dermatol 2010:62:646-54.)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available